10-Step Guide for a Smooth CE to UKCA Transition

CE marking will continue to be accepted in Great Britain until 30 June 2028 for medical devices. It will be accepted until 30 June 2030 for IVDs. Then, UKCA marking will become mandatory. Manufacturers should prepare now by appointing a UK Responsible Person. Additionally, they should update technical files and plan dual marking strategies for EU and UK access. In this blog, we have provided a step-by-step guide to help you with a smooth CE to UKCA transition.

Key deadlines for CE to UKCA transition

• Medical devices: CE marking will continue to be accepted in Great Britain until 30 June 2028. After this date, UKCA marking becomes mandatory for all medical devices placed on the GB market.
• In vitro diagnostics: CE marking will remain valid in Great Britain until 30 June 2030. From 1 July 2030 onward, UKCA marking is required for IVDs.
• Northern Ireland: Under the Windsor Framework, CE marking will remain mandatory indefinitely. UKCA marking is not recognized for NI market access.
• Dual marking period: Manufacturers may affix both CE and UKCA marks during the transition. This allows products to circulate in both EU/NI and GB markets without separate production lines.
• Post‑transition enforcement: From July 2028 (medical devices) and July 2030 (IVDs), MHRA will enforce UKCA compliance. Non‑UKCA devices will be barred from GB market entry.

Regulatory authorities

We have listed some of the regulatory authorities involved in CE to UKCA transition.

• Medicines and Healthcare products Regulatory Agency (MHRA): The MHRA is the UK’s competent authority overseeing medical device and IVD regulation. It enforces UKCA compliance, manages device registration, and monitors post‑market surveillance.
• UK approved bodies: These are UK‑designated conformity assessment organizations authorized to issue UKCA certificates. They function similarly to EU Notified Bodies but operate under UK MDR 2002 (as amended).
• EU notified bodies: EU notified bodies remain responsible for CE certification under MDR and IVDR. Their certificates will be valid in the EU/EEA and Northern Ireland but not in Great Britain after transition deadlines.
• UK Responsible Person (UKRP): Non‑UK manufacturers must appoint a UKRP to act as their regulatory liaison. The UKRP ensures MHRA registration, compliance oversight, and serves as the point of contact for authorities.

Step-by-step guide for CE to UKCA transition

We have prepared a detailed guide for smooth CE to UKCA transition.

1. Understand transition deadlines: CE marking will be accepted in Great Britain until 30June 2028 for medical devices and 30 June 2030 for IVDs. After these dates, UKCA becomes mandatory for market access. Northern Ireland will continue to require CE under the Windsor Framework. Manufacturers must plan timelines based on these deadlines to avoid disruption and have a smooth CE to UKCA transition.
2. Map product portfolios: Identify which products currently rely on CE marking and will need UKCA certification. Categorize them by risk class, regulatory pathway, and notified body involvement. This mapping helps prioritize high‑risk or high‑volume products first. It also ensures resources are allocated efficiently across your portfolio.
3. Appoint a UK Responsible Person (UKRP): Non‑UK manufacturers must designate a UKRP to act as their regulatory liaison. The UKRP is responsible for device registration with MHRA and ensuring compliance. Contracts should clearly define responsibilities, liabilities, and communication protocols. Moreover, early appointment avoids bottlenecks during audits and submissions.
4. Engage with UK Approved Bodies: UKCA requires certification from UK Approved Bodies listed in UKMCAB. Begin discussions early to secure capacity, as demand will rise closer to deadlines. Ensure they have scope for your product category and risk class. Maintain dual relationships with EU Notified Bodies for CE and UK Approved Bodies for UKCA.
5. Update technical documentation: Revise technical files to reference UK regulations and designated standards instead of EU directives. Ensure risk assessments, clinical evaluations, and post‑market surveillance plans align with UK MDR 2002 (as amended). Moreover, documentation must be audit‑ready and consistent across CE and UKCA submissions. Harmonization reduces duplication and errors.
6. Revise labeling and packaging: Add the UKCA mark with minimum height 5mm and it should be visible, legible, and indelible. Ensure labeling references UK regulations and includes UKRP details if applicable. Dual marking (CE + UKCA) is allowed during transition. However, clarity is essential to avoid confusion. Packaging updates should be validated for readability and durability.
7. Register devices with MHRA: All UKCA devices must be registered with MHRA before being placed on the GB market. Registration timelines vary by device class. Hence, plan accordingly. Ensure accurate submission of product details, certificates, and UKRP information. Keep records updated to avoid enforcement risks.
8. Align QMS with UK requirements: ISO 13485 remains the baseline. However, QMS must reflect UK‑specific obligations. Include vigilance reporting, complaint handling, and CAPA aligned with MHRA expectations. Supplier audits should incorporate UKCA compliance criteria. Regular internal audits ensure readiness for regulatory inspections.
9. Monitor regulatory divergence: UK may revise UK MDR independently of EU MDR/IVDR. Track MHRA consultations, guidance updates, and stakeholder communications. Build flexibility into compliance systems to adapt quickly. Regulatory intelligence is critical to avoid last‑minute surprises.
10. Train teams and communicate: Educate regulatory, quality, and commercial teams on UKCA requirements. Provide checklists, SOPs, and timelines for smooth execution. Communicate changes to distributors, suppliers, and customers to maintain trust. A well‑trained team reduces compliance risks and accelerates transition.

10 Pro tips to prepare for transition

1. Start early with gap analysis: Conduct a structured gap analysis between EU MDR/IVDR and UK MDR 2002 requirements. This will highlight documentation, labeling, and QMS areas needing updates. Early identification reduces compliance risk and avoids costly rework. This is a vital step for smooth CE to UKCA transition.
2. Secure UK approved body capacity: Demand for UK Approved Bodies will spike closer to 2028/2030 deadlines. Engage them now to lock in certification slots for your product classes. Moreover, confirm their scope matches your device type and risk class.
3. Dual marking strategy: Plan for CE + UKCA dual marking during the transition period. This avoids separate production lines and maintains access to both EU/NI and GB markets.
4. Strengthen UKRP contracts: If you are outside the UK, appoint a UK Responsible Person with clear contractual obligations. Define responsibilities for MHRA registration, vigilance reporting, and communication. A strong UKRP relationship reduces regulatory friction.
5. Update QMS for UK specifics: ISO 13485 compliance remains central but integrate UK‑specific vigilance and CAPA requirements. Add MHRA reporting timelines and UKRP oversight into SOPs. Additionally, supplier audits should include UKCA readiness criteria.
6. Revise labeling and IFUs: Ensure UKCA mark (≥5mm) is added alongside CE during transition. Include UKRP details on labels and IFUs where required. Validate readability, durability, and compliance with MHRA guidance.
7. Register devices with MHRA early: MHRA registration is mandatory before GB market entry. Keep registration data accurate and updated. Early registration builds regulatory goodwill and reduces enforcement risk.
8. Monitor MHRA consultations: UK regulations may diverge from EU MDR/IVDR over time. Track MHRA consultations, stakeholder updates, and draft guidance. Build flexibility into compliance systems to adapt quickly.
9. Train teams and suppliers: Educate internal teams and external suppliers on UKCA requirements. Provide checklists, SOPs, and transition timelines. Supplier scorecards should include UKCA readiness criteria. A trained ecosystem reduces compliance risks across the supply chain.
10. Build a transition timeline: Create a roadmap from 2026 to 2030 with milestones for UKCA enforcement and MHRA initiatives (UDI, eIFU). Align this with product launches, audits, and supplier reviews. A disciplined timeline ensures operational discipline and smooth CE to UKCA transition.

Email at [email protected] or call/Whatsapp on 9996859227 for a smooth CE to UKCA transition and any other regulatory support.